What is the Fiscal Year for Phio Pharmaceuticals?
Date: November 14, 2026
Phio Pharmaceuticals's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
King of Prussia, Pennsylvania
Industry
Biotechnology Research
Stock Symbol
PHIO
Website
https://phiopharma.comDescription
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biopharmaceutical company whose proprietary INTASYL siRNA technology makes our bodies’ immune cells more effective in killing tumor cells. INTASYL is the only self-delivering siRNA technology focused on immuno-oncology therapeutics. Phio was co-founded by a Nobel Laureate for discovery of RNAi. This discovery was leveraged to develop INTASYL, our broadly patented synthetic short interfering RNA (siRNA) drug technology. INTASYL is precisely designed to specifically silence targeted gene in the human body, causing our immune cells to be more effective in killing tumor cells. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Phio Pharmaceuticals and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.